LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.15 4.55

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.13

Max

1.16

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+334.78% upside

Turustatistika
By TradingEconomics
Turukapital	-2.3M 123M
Eelmine avamishind	-3.4
Eelmine sulgemishind	1.15

Uudiste sentiment

By Acuity

13%

87%

9 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. dets 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. dets 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. dets 2025, 22:32 UTC

Tulu

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 20:45 UTC

Tulu

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. dets 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. dets 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. dets 2025, 19:23 UTC

Tulu

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. dets 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. dets 2025, 18:33 UTC

Omandamised, ülevõtmised, äriostud

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. dets 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. dets 2025, 17:49 UTC

Tulu

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. dets 2025, 17:34 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12. dets 2025, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12. dets 2025, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12. dets 2025, 17:32 UTC

Omandamised, ülevõtmised, äriostud

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12. dets 2025, 17:31 UTC

Omandamised, ülevõtmised, äriostud

Orange to Buy the Stake for EU4.25B in Cash

12. dets 2025, 17:24 UTC

Market Talk

Argentina Predicts Record Wheat Crop -- Market Talk

12. dets 2025, 17:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

12. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 17:18 UTC

Market Talk

Tulu

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12. dets 2025, 17:09 UTC

Market Talk

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12. dets 2025, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. dets 2025, 16:47 UTC

Market Talk

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12. dets 2025, 16:39 UTC

Market Talk

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12. dets 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12. dets 2025, 16:15 UTC

Tulu

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12. dets 2025, 15:35 UTC

Tulu

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 14:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

334.78% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 334.78%

Kõrge 8 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

9 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.